Orforglipron (Eli Lilly) is the first non-peptide oral GLP-1 receptor agonist a small molecule rather than an injected peptide, with no SNAC absorption-enhancer required and an FDA decision is anticipated in 2026
In a 72-week Zepbound (tirzepatide) study of adults without diabetes, average weight loss was 15.0% (34 lbs) for 5 mg, 19.5% (44 lbs) for 10 mg, 20.9% (48 lbs) for 15 mg, and 3.1% (7 lbs) for placebo
The 14 days between sessions are when the dermal response unfolds and when supporting actives do their work
Estrogens can act as pro-oxidant or anti-oxidant agents depending on cell types and ratio of different types of estrogen receptors
CD154/CD40 Another pair of co-stimulatory receptor-ligand system whose engagement has profound effects on B, dendritic and endothelial cells is the CD40-CD40 ligand (CD154)
GLP-1 Body Composition Meta-Analysis Methods In the present study, researchers evaluated the efficacy of GLP-1RAs and dual GLP-1/GIP agonists in modulating body composition and promoting weight loss in adults with overweight or obesity with or without type 2 diabetes (T2D)
